Since lineage plasticity relies on differential TF activities and their corresponding transcriptional output, we first explored which TF regulate the TIS-associated lymphoma transcriptome that we previously reported after in vitro-exposure to the anthracycline chemo drug adriamycin (ADR, a.k.a. doxorubicin)39, encompassing transcripts that distinguish senescent Eμ-myc;bcl2 (hereafter referred to as control;bcl2) from equally ADR-treated but senescence-incapable Suv39h1-deficient Eμ-myc;bcl2 (i.e. Suv39h1–;bcl2) lymphomas and their respective untreated matches. The gene discussed is SUV39H1; the disease is lymphoma.